These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11992782)

  • 1. Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
    Fujita M; Seki T
    Bioorg Med Chem Lett; 2002 May; 12(10):1383-6. PubMed ID: 11992782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
    Fujita M; Seki T; Inada H; Shimizu K; Takahama A; Sano T
    Bioorg Med Chem Lett; 2002 Mar; 12(5):771-4. PubMed ID: 11858999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs.
    Fujita M; Seki T; Inada H; Shimizu K; Takahama A; Sano T
    Bioorg Med Chem Lett; 2002 Feb; 12(3):341-4. PubMed ID: 11814792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins.
    Giembycz MA; Kroegel C; Barnes PJ
    J Immunol; 1990 May; 144(9):3489-97. PubMed ID: 2158510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Matsuura M; Kawakami Y; Terasawa M
    Inflamm Res; 1997 Apr; 46(4):147-53. PubMed ID: 9137994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series.
    Weber KH; Heuer H
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):82-7. PubMed ID: 2540098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
    Cai X; Scannell RT; Yaeger D; Hussoin MS; Killian DB; Qian C; Eckman J; Hwang SB; Libertine-Garahan L; Yeh CG; Ip SH; Shen TY
    J Med Chem; 1998 May; 41(11):1970-9. PubMed ID: 9599246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
    Michaux C; Dogné JM; Norberg B; Durant F; Masereel B
    Acta Crystallogr C; 2002 Oct; 58(Pt 10):o621-3. PubMed ID: 12359948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor. Roles of thromboxanes and leukotrienes.
    Nagase T; Ishii S; Katayama H; Fukuchi Y; Ouchi Y; Shimizu T
    Am J Respir Crit Care Med; 1997 Nov; 156(5):1621-7. PubMed ID: 9372685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats.
    de la Cruz JP; Moreno A; Ruiz-Ruiz MI; García-Campos J; Sánchez de la Cuesta F
    Eur J Pharmacol; 1998 Oct; 360(1):37-42. PubMed ID: 9845270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.
    Macconi D; Benigni A; Morigi M; Ubiali A; Orisio S; Livio M; Perico N; Bertani T; Remuzzi G; Patrono C
    J Lab Clin Med; 1989 May; 113(5):549-60. PubMed ID: 2541212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep.
    Christman BW; Lefferts PL; Blair IA; Snapper JR
    Am Rev Respir Dis; 1990 Dec; 142(6 Pt 1):1272-8. PubMed ID: 2174655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial agonist effect of the platelet-activating factor receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart.
    Hu W; McNicholl IK; Choy PC; Man RY
    Br J Pharmacol; 1993 Oct; 110(2):645-50. PubMed ID: 8242237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxic pulmonary vasoconstriction in isolated blood-perfused rat lung; modulation by thromboxane A2, platelet-activating factor, cysteinyl leukotrienes and endothelin-1.
    Chłopicki S; Bartuś JB; Gryglewski RJ
    Pol J Pharmacol; 2002; 54(5):433-41. PubMed ID: 12593530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of constitutive nitric oxide with PAF and thromboxane on rat intestinal vascular integrity in acute endotoxaemia.
    László F; Whittle BJ; Moncada S
    Br J Pharmacol; 1994 Dec; 113(4):1131-6. PubMed ID: 7889265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives.
    Takeuchi K; Kohn TJ; Mais DE; True TA; Wyss VL; Jakubowski JA
    Bioorg Med Chem Lett; 1998 Aug; 8(15):1943-8. PubMed ID: 9873463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of platelet-activating factor (PAF) receptor stimulates nitric oxide (NO) release via protein kinase C-alpha in HEC-1B human endometrial epithelial cell line.
    Dearn S; Rahman M; Lewis A; Ahmed Z; Eggo MC; Ahmed A
    Mol Med; 2000 Jan; 6(1):37-49. PubMed ID: 10803407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes.
    Svetlov SI; Barton JM; Olson MS
    Life Sci; 1996; 58(5):PL 81-6. PubMed ID: 8594301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
    Koike H; Imanishi N; Natsume Y; Morooka S
    Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists.
    Hurst JS; Bazan HE
    J Ocul Pharmacol Ther; 1995; 11(3):329-37. PubMed ID: 8590265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.